CRNX
Income statement / Annual
Last year (2024), Crinetics Pharmaceuticals, Inc.'s total revenue was $1.04 M,
a decrease of 74.11% from the previous year.
In 2024, Crinetics Pharmaceuticals, Inc.'s net income was -$298.41 M.
See Crinetics Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.04 M |
$4.01 M |
$4.74 M |
$1.08 M |
$71.00 K |
$1.19 M |
$2.43 M |
$2.05 M |
$589.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$1.39 M
|
$1.26 M
|
$57.00 M
|
$1.11 M
|
$24.48 M
|
$9.23 M
|
$5.10 M
|
| Gross Profit |
-$1.75 M
|
$4.01 M
|
$3.35 M
|
-$184.00 K
|
-$56.93 M
|
$80.00 K
|
-$22.05 M
|
-$7.19 M
|
-$4.51 M
|
| Gross Profit Ratio |
-1.68
|
1
|
0.71
|
-0.17
|
-801.79
|
0.07
|
-9.08
|
-3.51
|
-7.66
|
| Research and Development Expenses |
$240.16 M
|
$168.53 M
|
$130.23 M
|
$84.26 M
|
$57.00 M
|
$41.51 M
|
$24.48 M
|
$9.23 M
|
$5.10 M
|
| General & Administrative Expenses |
$99.74 M
|
$58.09 M
|
$42.39 M
|
$24.53 M
|
$18.03 M
|
$13.52 M
|
$6.66 M
|
$1.94 M
|
$1.53 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$99.74 M
|
$58.09 M
|
$42.39 M
|
$24.53 M
|
$18.03 M
|
$13.52 M
|
$6.66 M
|
$1.94 M
|
$1.53 M
|
| Other Expenses |
$0.00
|
$0.00
|
$4.97 M
|
$61.00 K
|
-$71.00 K
|
-$1.19 M
|
$1.60 M
|
-$48.00 K
|
-$1.00 K
|
| Operating Expenses |
$339.89 M
|
$226.62 M
|
$172.62 M
|
$108.78 M
|
$74.95 M
|
$53.83 M
|
$28.71 M
|
$9.13 M
|
$6.04 M
|
| Cost And Expenses |
$339.89 M
|
$226.62 M
|
$172.62 M
|
$108.78 M
|
$74.95 M
|
$53.83 M
|
$28.71 M
|
$9.13 M
|
$6.04 M
|
| Interest Income |
$41.44 M
|
$13.44 M
|
$4.32 M
|
$157.00 K
|
$991.00 K
|
$3.46 M
|
$1.75 M
|
$26.00 K
|
$37.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$4.32 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.00 K
|
$11.00 K
|
| Depreciation & Amortization |
$0.00
|
$1.10 M
|
$1.39 M
|
$1.26 M
|
$1.23 M
|
$1.11 M
|
$471.00 K
|
$128.00 K
|
$92.00 K
|
| EBITDA |
-$338.85 M |
-$221.51 M |
-$166.90 M |
-$106.78 M |
-$72.59 M |
-$49.31 M |
-$28.24 M |
-$9.00 M |
-$5.95 M |
| EBITDA Ratio |
-326.13
|
-55.2
|
-35.23
|
-99.05
|
-1022.34
|
-41.33
|
-11.63
|
-4.4
|
-10.11
|
| Operating Income Ratio |
-326.13
|
-55.47
|
-35.44
|
-99.91
|
-1055.68
|
-45.12
|
-11.82
|
-4.46
|
-10.26
|
| Total Other Income/Expenses Net |
$40.45 M
|
$8.08 M
|
$3.96 M
|
$61.00 K
|
$1.14 M
|
$3.41 M
|
$1.60 M
|
-$30.00 K
|
$25.00 K
|
| Income Before Tax |
-$298.41 M
|
-$214.53 M
|
-$163.92 M
|
-$107.64 M
|
-$73.81 M
|
-$50.42 M
|
-$27.12 M
|
-$9.16 M
|
-$6.02 M
|
| Income Before Tax Ratio |
-287.21
|
-53.46
|
-34.6
|
-99.85
|
-1039.61
|
-42.26
|
-11.17
|
-4.48
|
-10.22
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$3.96 M
|
-$922.00 K
|
-$948.00 K
|
-$887.00 K
|
$1.60 M
|
-$40.00 K
|
$10.00 K
|
| Net Income |
-$298.41 M
|
-$214.53 M
|
-$159.95 M
|
-$106.72 M
|
-$72.86 M
|
-$49.54 M
|
-$27.12 M
|
-$9.16 M
|
-$6.02 M
|
| Net Income Ratio |
-287.21
|
-53.46
|
-33.77
|
-99
|
-1026.25
|
-41.52
|
-11.17
|
-4.48
|
-10.22
|
| EPS |
-3.69 |
-3.69 |
-3.08 |
-2.78 |
-2.39 |
-2.05 |
-2.23 |
-0.66 |
-0.43 |
| EPS Diluted |
-3.69 |
-3.69 |
-3.08 |
-2.78 |
-2.39 |
-2.05 |
-2.23 |
-0.66 |
-0.43 |
| Weighted Average Shares Out |
$80.78 M
|
$58.07 M
|
$51.98 M
|
$38.44 M
|
$30.45 M
|
$24.18 M
|
$12.14 M
|
$13.88 M
|
$13.88 M
|
| Weighted Average Shares Out Diluted |
$80.78 M
|
$58.07 M
|
$51.98 M
|
$38.44 M
|
$30.45 M
|
$24.18 M
|
$12.14 M
|
$13.88 M
|
$13.88 M
|
| Link |
|
|
|
|
|
|
|
|
|
